A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome
NCT00830518
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
57
Enrollment
INDUSTRY
Sponsor class
Conditions
Acute Myelogenous Leukemia
High-Grade Myelodysplastic Syndrome
Interventions
DRUG:
Alisertib
Sponsor
Millennium Pharmaceuticals, Inc.